Literature DB >> 21041567

Peramivir for severe influenza infection in a patient with diabetic nephropathy.

Tatsuyo Nasu, Daisuke Ogawa, Jun Wada, Hirofumi Makino.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21041567     DOI： 10.1164/ajrccm.182.9.1209

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  5 in total

1.  Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients.

Authors:  Shigeru Kohno; Hiroshi Kida; Masashi Mizuguchi; Nobuo Hirotsu; Tadashi Ishida; Junichi Kadota; Jingoro Shimada
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

Review 2.  Two years after pandemic influenza A/2009/H1N1: what have we learned?

Authors:  Vincent C C Cheng; Kelvin K W To; Herman Tse; Ivan F N Hung; Kwok-Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

Review 3.  Antioxidant therapy as a potential approach to severe influenza-associated complications.

Authors:  Noboru Uchide; Hiroo Toyoda
Journal:  Molecules       Date:  2011-02-28       Impact factor: 4.411

4.  Efficacy and Safety of Intravenous Peramivir Compared With Oseltamivir in High-Risk Patients Infected With Influenza A and B Viruses: A Multicenter Randomized Controlled Study.

Authors:  Shigeki Nakamura; Taiga Miyazaki; Koichi Izumikawa; Hiroshi Kakeya; Yutaka Saisho; Katsunori Yanagihara; Yoshitsugu Miyazaki; Hiroshi Mukae; Shigeru Kohno
Journal:  Open Forum Infect Dis       Date:  2017-06-19       Impact factor: 3.835

5.  Clinical Effectiveness of Intravenous Peramivir versus Oseltamivir for the Treatment of Influenza in Hospitalized Patients.

Authors:  Jin Seo Lee; Mi Suk Lee; Yoonseon Park; Jacob Lee; Eun-Jeong Joo; Joong Sik Eom
Journal:  Infect Drug Resist       Date:  2020-05-19       Impact factor: 4.003
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.